DEE 1 5 2003 U

۵ ۵	Str						Shee	t <u>1</u> of	1
POSDETPTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE MATION DISCLOSURE STATEMENT BY APPLICANT			ATTY. DOCKET NO.: OC01629K APPLICANT: Michael P. Dwyer et a		APPLICATION NO.: 10/664,337		
(Use several sheets if necessa				arv)	FILING DATE:		GROUP:		
<del></del>	•			TENT DOCUM	09/17/2003		1	<del> </del>	<del>-</del>
*EXAMINER		DOCUMENT	DATE	NAME NAME		CLASS	SUB-	FILING APPRO	
	AA	US 6,107,305	08/22/2000	Misra	et al.		CENCO	IXI I KO	TIVATE
	AB								
	AC			ļ					
·	AD								-
	AE			ļ		ļ			
	AF		-			<del> </del>	ļ		<del></del>
	AG		-		·	<del> </del>	<del> </del>		
	AI					<del>-</del>	<u> </u>	-	
	AJ								-
	AK		-	<del> </del>	<del></del>				<del></del>
	1	<u> </u>	ODEICN	DATENT DOC	LINACNITO			<u> </u>	
	1	DOCUMENT	DATE	PATENT DOC	UNEN 15	TOLACC	LOUID	ITDANO	ATION
		NUMBER	DATE	COUNTRY	•	CLASS	SUB- CLASS	TRANS	_
10	AL		05/25/2001	PC	<del></del>	<del>                                     </del>	CLASS	160	NO
	AM	***************************************	00/20/2001	<del></del>	<u> </u>				<u> </u>
	AN					<del> </del>	<del>                                     </del>	<del>                                     </del>	<del>                                     </del>
	AO						<del> </del>		<del> </del>
	AP					<del>                                     </del>	<del></del>		<del> </del>
	OTI	HER DOCUMENT	S (Includi	na Author Title	Data Part	inont Pa	acc Et	<u> </u>	<u> </u>
	AQ	HER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", Eur. J. Biochem (1994), 224: 771-786.							
	AR			Lof Continuous In	fusion Flavori	idal a Na	val Civalia		-d 4
	-	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms", Journal of Clinical Oncology							
<u> </u>		(September 1998), 16(9): 2986-2999.							
	AS	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", Eur. J. Biochem. (1997), 243: 527-536.							
	AT	Bible et al., "Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", Cancer Research (August							
		<u> </u>	3380.					·	•
	AU	Shiota et al., "Synthe	esis and Stru	cture-Activity Rela	ationship of a N	lew Serie	s of Poter	nt Angio	tensin
<b>/</b>		II Receptor Antagoni	ists: Pyrazolo	$o[1,5-\alpha]$ pyrimidine	", Chem. Phari	m. Bull. (1	999), 47(	7): 928-	938.
	AV	Yasuo Makisumi <i>et a</i>	al., "Studies d	on the Azaindolizii	ne Compounds	s. XI. Synt	hesis of 6	5,7-	
Y	010/	Disubstituted Pyrazo	10[7,5-α]pyri	midines.", Chem F	Pharm. Bull. (1	962), 10: (	<u>520-626.</u>		
	AW	Aboul-Fadl et al., "Ef Pakadium-Catalyzed	Tective and \	variable Functions	alization of Pyra	azolo[1,5-	α]pyridine	es Involv	ring
EXAMINER		- dyadidii Evataiyzed	Cooping Re		SIS 2000, (12):	1121-113	۷.	··	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.